Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron
Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This research aimed to analyze the impact of genetic variation on mirabegron pharmacokinetics and safety. Volunteers from three bio...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/16/8/1077 |